Last reviewed · How we verify
ceftriaxone 1gm for intravenous infusion
Ceftriaxone works by inhibiting bacterial cell wall synthesis through inhibition of the enzyme penicillin-binding protein 1B.
Ceftriaxone works by inhibiting bacterial cell wall synthesis through inhibition of the enzyme penicillin-binding protein 1B. Used for Community-acquired pneumonia, Skin and skin structure infections.
At a glance
| Generic name | ceftriaxone 1gm for intravenous infusion |
|---|---|
| Also known as | cefaxon |
| Sponsor | Ain Shams Maternity Hospital |
| Drug class | Cephalosporin antibiotic |
| Target | Penicillin-binding protein 1B |
| Modality | Small molecule |
| Therapeutic area | Infectious disease |
| Phase | Phase 3 |
Mechanism of action
This results in the disruption of the bacterial cell wall, ultimately leading to cell lysis and death. Ceftriaxone is a third-generation cephalosporin antibiotic.
Approved indications
- Community-acquired pneumonia
- Skin and skin structure infections
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Abdominal pain
- Allergic reactions
Key clinical trials
- Antibiotics as an Adjuvant in Patients With Acute Severe Ulcerative Colitis (PHASE2)
- Antibiotic Prophylaxis for Elective Cesarean Section (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: